Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combination, and placebo control. The 12-week intervention represents the first systematic evaluation of Urolithin A's potential to resynchronize circadian rhythms and mitigate age-related sleep disturbances.
Key Study Design Features:
Inclusion Criteria: Targets subclinical individuals with impaired sleep quality (PSQI score >5) but no pathological diagnosis, excluding those dependent on caffeine/alcohol.Multidimensional Assessment:Subjective: Sleep quality scores, chronotype questionnaire, daytime dysfunction scales.Objective: Continuous actigraphy monitoring, polysomnography (PSG) analysis.Biomarkers: NAD+ levels, DNA methylation age, inflammatory markers (IL-6, TNF-α), cortisol rhythm, circadian proteins (BMAL1, PER2), insulin resistance (HOMA-IR), immunoglobulin levels.
"We aim to uncover the causal link between sleep disorders and ageing using epigenetic clocks and metabolic markers, beyond just tracking sleep duration," stated Professor Chen, the lead investigator. "Combining Urolithin A, a circadian regulator, with the senolytic Fisetin explores synergy for novel solutions, like menopausal sleep issues."
Scientific Commitment: Building a Health Ecosystem
As a leading high-quality ingredient producer, Bonerge's R&D follows a pipeline of 'ingredient science, mechanistic research, clinical translation'. The company is actively seeking global clinical partners from academia and industry to explore Urolithin A's potential in sleep health and cellular ageing intervention.
Amidst the anti-ageing industry's shift from consumerism to scientific rigor, Bonerge positions Urolithin A not just as a standalone ingredient, but as a catalyst for evidence-based solutions. Focused on core mechanisms like cellular senescence, Bonerge develops innovative ingredients targeting cellular health, forming a robust "health ecosystem." Key components include:
Fisetin: Potent senolytic selectively clearing senescent cells and reducing their formation, retarding aging in skin, ovarian, and neural tissues.Urolithin A: Regulates circadian rhythms, boosts endogenous NAD+ synthesis, enhances cellular repair, and improves sleep quality and reproductive health.L-Ergothioneine: Unique antioxidant with a dedicated transporter (OCTN1), accumulating in high-stress tissues to neutralize ROS, protecting DNA and telomeres.PQQ Disodium: Activates the PGC-1α/PPARγ pathway, driving mitochondrial DNA replication and biogenesis.S-Equol: Natural, non-steroidal estrogenic metabolite with high affinity for ERβ, offering a safer alternative for menopause health.
About Bonerge
Bonerge firmly contends that the future of anti-ageing hinges on evidence-based solutions. These solutions are grounded in well-defined biological mechanisms, supported by robust scientific data, and tailored to precise applications, ultimately delivering comprehensive, science-validated health benefits. For more detailed information about our clinical findings, discover more about us at http://www.bonerge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250708112969/en/
Contacts
Cecilia Yangsales@bonerge.com
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Tesla Awards Musk $29 Billion in Shares as 2018 Pay Battle Continues
Tesla (TSLA, Financials) granted CEO Elon Musk an interim award of 96 million shares, valued at about $29 billion, while his disputed $56 billion 2018 compensation package remains under review by the Delaware Supreme Court. The award will vest in two years if Musk stays as CEO or in another top role. It will be forfeited if the court clears the 2018 package, which was previously struck down by a Delaware judge as improperly approved. Shareholders re?approved that plan in June 2024. The move follows Tesla's weak quarterly results, with sales falling for a second straight quarter and automotive revenue down 16%. Musk warned of possible rough quarters ahead as EV tax credit cuts loom. The company will hold another shareholder meeting in November. This article first appeared on GuruFocus.
Yahoo
11 minutes ago
- Yahoo
American Alcohol-Free Association Celebrates 5 Years of Promoting Sobriety and Healthier Lifestyles
In 2023, 12,429 People Died in Alcohol-Impaired Driving Crashes Miami, Florida--(Newsfile Corp. - August 4, 2025) - Founded in 2020 by visionary entrepreneur Reynald Vito Grattagliano, the American Alcohol-Free Association (AAFSA) proudly celebrates five years of empowering people to live sober and healthier lives. Supported by Arkay Beverages and Beyond Spirits, AAFSA has become a leading voice in the alcohol-free and zero-proof movement across the United States and beyond. AAFSA Created in response to the growing demand for health-conscious and alcohol-free alternatives, AAFSA serves as a community platform for both consumers and brands who believe in the benefits of sobriety. "When we launched AAFSA in 2020, our mission was to inspire people to enjoy life without alcohol," said Reynald Vito Grattagliano, President and Founder of AAFSA. "Five years later, we are proud to see a growing community embracing zero-proof options, enjoying social moments without compromise, and making healthier lifestyle choices." The Life-Saving Impact of Sobriety Alcohol consumption continues to pose a major public health risk in the United States: Drunk driving kills 34 people every day-that's one person every 42 minutes. In 2023 alone, 12,429 lives were lost in alcohol-impaired driving crashes. (Source: NHTSA) About 20,000 U.S. adults die each year from alcohol-associated cancers, most of which could have been prevented by following recommended drinking limits. (Source: CDC) These tragic and preventable losses destroy families and communities. Behind every statistic is a family grieving a loved one. Reynald Vito Grattagliano An Invitation to Beverage Makers: Join Forces for a Happier World The American Alcohol-Free Association is calling on all beverage makers-alcohol-free producers, soda brands, and spirits companies-to join forces to prevent this ongoing tragedy. "We want a happier world, and we want happy families-not families destroyed by the loss of their loved ones to alcohol-related tragedies," said Grattagliano. "Together, we can create a cultural shift where choosing alcohol-free options becomes the norm and where enjoyment never comes at the cost of a life." Join the Movement AAFSA invites leading alcohol-free and zero-proof brands to unite their efforts and accelerate the shift toward sobriety. Consumers and supporters are encouraged to join the association and access exclusive resources at With the continuous rise of mocktails, alcohol-free spirits, and wellness-oriented socializing, the American Alcohol-Free Association is shaping the future of responsible enjoyment-where sobriety is a celebration, not a limitation. Press Contact: Person Name: Reynald Vito GrattaglianoCompany Name:Alcohol-Free AssociationEmail: info@ To view the source version of this press release, please visit
Yahoo
11 minutes ago
- Yahoo
Kyndryl (NYSE:KD) Misses Q2 Sales Targets, Stock Drops 13%
IT infrastructure services provider Kyndryl (NYSE:KD) fell short of the market's revenue expectations in Q2 CY2025, with sales flat year on year at $3.74 billion. Next quarter's revenue guidance of $3.81 billion underwhelmed, coming in 1.5% below analysts' estimates. Its non-GAAP profit of $0.37 per share was in line with analysts' consensus estimates. Is now the time to buy Kyndryl? Find out in our full research report. Kyndryl (KD) Q2 CY2025 Highlights: Revenue: $3.74 billion vs analyst estimates of $3.80 billion (flat year on year, 1.5% miss) Adjusted EPS: $0.37 vs analyst estimates of $0.36 (in line) Adjusted EBITDA: $647 million vs analyst estimates of $628 million (17.3% margin, 3% beat) Revenue Guidance for Q3 CY2025 is $3.81 billion at the midpoint, below analyst estimates of $3.87 billion Operating Margin: 4%, up from 2.5% in the same quarter last year Free Cash Flow was -$267 million compared to -$27.75 million in the same quarter last year Market Capitalization: $8.42 billion "Our first quarter reflected steady progress across key growth areas of our business, with contributions from Kyndryl Consult, hyperscaler-related activity, scope expansions and productivity gains. Our expertise in mission-critical technology and our unique operational capabilities, including Kyndryl Bridge, are helping customers innovate and creating new growth opportunities for Kyndryl," said Chairman and Chief Executive Officer Martin Schroeter. Company Overview Born from IBM's managed infrastructure services business in a 2021 spinoff, Kyndryl (NYSE:KD) is the world's largest IT infrastructure services provider that designs, builds, and manages technology environments for enterprise customers. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. With $15.06 billion in revenue over the past 12 months, Kyndryl is a behemoth in the business services sector and benefits from economies of scale, giving it an edge in distribution. This also enables it to gain more leverage on its fixed costs than smaller competitors and the flexibility to offer lower prices. However, its scale is a double-edged sword because it's harder to find incremental growth when you've penetrated most of the market. To expand meaningfully, Kyndryl likely needs to tweak its prices, innovate with new offerings, or enter new markets. As you can see below, Kyndryl struggled to generate demand over the last five years. Its sales dropped by 4.6% annually, a tough starting point for our analysis. Long-term growth is the most important, but within business services, a half-decade historical view may miss new innovations or demand cycles. Kyndryl's recent performance shows its demand remained suppressed as its revenue has declined by 5.7% annually over the last two years. This quarter, Kyndryl's $3.74 billion of revenue was flat year on year, falling short of Wall Street's estimates. Company management is currently guiding for a 1% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 3.4% over the next 12 months. While this projection implies its newer products and services will spur better top-line performance, it is still below the sector average. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Although Kyndryl was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 3.2% over the last five years. Unprofitable business services companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Kyndryl's operating margin rose by 11.5 percentage points over the last five years. Still, it will take much more for the company to show consistent profitability. In Q2, Kyndryl generated an operating margin profit margin of 4%, up 1.5 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Kyndryl's full-year EPS flipped from negative to positive over the last two years. This is encouraging and shows it's at a critical moment in its life. In Q2, Kyndryl reported adjusted EPS at $0.37, up from $0.13 in the same quarter last year. This print beat analysts' estimates by 1.8%. Over the next 12 months, Wall Street expects Kyndryl's full-year EPS of $1.41 to grow 89.1%. Key Takeaways from Kyndryl's Q2 Results It was encouraging to see Kyndryl beat analysts' EPS expectations this quarter. On the other hand, its revenue slightly missed and its revenue guidance for next quarter fell short of Wall Street's estimates. Overall, this was a weaker quarter. The stock traded down 13% to $31.92 immediately after reporting. Kyndryl didn't show it's best hand this quarter, but does that create an opportunity to buy the stock right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
